Use of biomarkers in research by dos Santos Silva, Isabel
  
 
 
Isabel dos Santos Silva 
 
LSHTM, 4 April 2013 
 
Use of biomarkers in research 
Faculty of Epidemiology and Population Health 
Improving health worldwide www.lshtm.ac.uk 
What is a biomarker? 
 
 
 A biological marker (abbreviated to biomarker) is a 
substance or structure measured in body tissues, 
fluids or body products.  
 
 Endobiotic (if normally present in the body) 
 
 Xenobiotic (if foreign to the body) 
 
“Molecular epidemiology” 
Examples of biomarkers 
Examples of disease associated biomarkers  
Measuring the immeasurable… 
This is a rapidly advancing field… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
James Watson & 
Francis Crick 
 
Nobel Prize, 1962 
The discovery of the double helix 
structure of the DNA, 1953 
In 2003 - just 50 years later – the sequence of the entire human 
genome was completed.  
The Human Genome Project 
Nature – 21 October 2004 
(431 :931-945) 

From DNA to proteins… 
The shape of things to come… 
 
The shape of things to come… 
Epigenetics 

 The shape of things to come… 
very large-scale! 
 
Belief that biomarkers have favourable 
characteristics relative to other methods: 
• Objective 
 
• Individualised (target to each individual at relevant 
times  
 
• More specific and sensitive 
 
Biomarkers in Social Sciences 
Aims: 
 
(i) To validate or complement other measurements (e.g. 
self-reports) 
 
(ii) To analyse interactions between social and biological 
factors 
 
(iii) To examine pathways and establish causation 
 
  
Traditional approach 
 
 
        ?????? 
“Black box approach” 
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Uses of biomarkers in research: 
                
 
 Improve measurement of exposure 
 
 
 Measure differences between individuals’ 
susceptibility to the effects of exposure or 
progression to disease 
 
 
 Provide measures of early outcome 
 
  
    
 
    
 
 
 
 
 
 
 
 
 
   
External exposure 
Internal exposure  blood 
 
(Stored in tissues) 
 
(Excreted - in 
     urine etc) 
Internal exposure 
 - at target cells 
 
Interaction between exposure 
and target cells (= BED) 
Early biological outcomes 
 
 
 
Biomarkers 
of 
exposure 
Biomarkers  
of  
outcome 
Biomarkers of internal dose 
Capture external exposure, absorption and sometimes 
metabolism by the body: 
 
 
 Chemical exposures: e.g. levels of Vitamin C in the 
blood or arsenic in the hair 
 
 
 
 Metabolites of exposures: e.g. levels of cotinine (a 
metabolite of tobacco) in the urine  
 
Biomarkers of internal dose 
Validation studies: 
 
 E.g. levels of cotinine in the urine measured in a sub-
sample to validate questionnaire data on current 
smoking habits  
 
  
    
 
    
 
 
 
 
 
 
 
 
 
   
External exposure 
Internal exposure  blood 
 
(Stored in tissues) 
 
(Excreted - in 
     urine etc) 
Internal exposure 
 - at target cells 
 
Interaction between exposure 
and target cells (= BED) 
Early biological outcomes 
 
 
 
Biomarkers 
of 
exposure 
Biomarkers  
of  
outcome 
      Biomarkers of biologically effective dose 
 
The interaction between the exposure and target cells 
represents the bridging stage between exposure and 
outcome – the biologically effective dose (BED) 
 
Carcinogen adducts 
Chemical carcinogens are genotoxic – they can damage DNA:  
 
 Carcinogens are metabolised inside the body, where they 
are either inactivated or activated 
 
 The activated carcinogen can bond with DNA or proteins in 
the target cells and in other tissues 
 
 Carcinogen-DNA or carcinogen-protein products are called 
adducts  
 
Chemical carcinogens 
– The adduct distorts the DNA structure.  If it is not repaired 
before the cell divides, part of the genetic code may be misread, 
resulting in a genetic mutation.   
 
– In most cells the affected DNA bases do not have a coding 
function - the mutations are ‘silent’.   
 
–   Some mutations may lead to changes in structure or function. 
These changes may result in cell death, or in development of 
cancers.  
 
Carcinogenic adducts 
Carcinogen adduct levels measure the biologically effective 
dose (BED) of the carcinogen.  
 
The BED represents the net effect of external exposure to the 
carcinogen as well as multiple internal metabolic steps: 
 
 absorption by the body 
 metabolic activation 
 DNA repair rates 
 target cell turnover 
 
Carcinogenic adducts 
 
If a group of individuals receive exactly the same external 
exposure would you expect them to have exactly the same 
biologically effective dose of that exposure? 
 
 
e.g. if they all smoke 20 of the same brand of cigarettes a day 
for the same number of years would they all have the same 
levels of nicotine-DNA adducts?  
Internal carcinogen exposure 
Metabolism               (Inactivated)                   
 
DNA  & protein 
adducts formed in 
non-target cells 
DNA & protein adducts 
formed in target cells 
(DNA adducts in 
exfoliated target 
cells) 
DNA damage 
(DNA repair) 
Mutation 
Where to measure carcinogen adduct levels  
 Target issues (ideal but usually invasive) 
 
 Exfoliated cells 
 
 Surrogate tissues or fluids 
• body fluids such as urine 
• peripheral blood:  
 
– Protein adducts are formed when the carcinogen binds to 
blood proteins such as haemoglobin or albumin. This 
method assumes that protein adduct formation parallels 
DNA adduct formation in target tissue. 
 
Internal carcinogen exposure 
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Organ cavities 
Studies nested within the cohort 
Time 
x 
x 
x 
Each line represents one subject 
x = case 
Start of follow-up End of follow-up 
Studies nested within the cohort 
For each case, one or more controls are selected among those who 
are still at risk (disease-free) at the time of diagnosis of the case.  
 
So, controls are matched to the cases on time 
x=case 
x=control  
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Studies nested within the cohort 
Controls matched to the cases on time – risk sets 
x=case 
x=control  
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Nested case-control design 
 Advantages: 
 Less costly (e.g. only need to conduct lab assays for the cases and 
controls rather than the whole cohort) 
 No need to collect exposure data for cases and controls beyond the 
time of follow-up of the case  
 Statistically-efficient 
 
 Disadvantages: 
 Requires selection of controls as cases arise (with eventual collection 
of additional exposure data) 
 Impossible to examine data using multiple time scales  (i.e. analyses 
will have to use the time scale on which controls were matched to the 
cases) 
 Controls selected for a particular outcome cannot be used to examine 
other outcomes 
 
 
• Aflatoxin - metabolic product of fungi of the Aspergillus spp. that 
grow on maize and peanut crops 
 
• Risk factor for liver cancer 
 
• Aflatoxin forms adducts with DNA in liver cells, which correlates 
with a mutation in codon 249 of the p53 gene 
 
• Descriptive studies conducted to determine the prevalence of 
aflatoxin-DNA adducts in liver biopsy samples from individuals 
with liver cancer  
Example:  
• Urine samples from 18,244 men in Shanghai. 
 
• ~70,000 person-years of follow up 
      55 cases of liver cancer ascertained.  
 
• The presence of aflatoxin adduct was compared in the stored 
urine samples from the individuals with liver cancer and from 
267 individuals without liver cancer, randomly selected from 
the cohort.   
 
• Positive association between the presence of urinary aflatoxin 
adduct and risk of liver cancer. 
             (Quian et al., 1994) 
Example:  
Case-cohort studies (risk ratio) 
Time 
x 
x 
x 
Random sample of the cohort 
(sub-cohort)   
All cases diagnosed 
during follow-up  
Start of follow-up End of follow-up 
x 
x 
x 
Case-cohort design 
 Advantages: 
 Less costly (e.g. only need to conduct lab assays for the cases 
and the sub-cohort) 
 The sub-cohort can be identified at the start of the follow-up 
 New cases do not require identification of new controls 
 The same sub-cohort can be used to examine multiple 
outcomes 
 The sub-cohort  can be used to estimates 
incidence/prevalence  
 Possible to examine multiple time scales 
 
 Disadvantages: 
 Requires constant up-date of exposure data for the whole 
sub-cohort 
 
 
Belief that biomarkers have several 
strengths: 
• Objective 
 
• Individualised (target to each individual at relevant 
times ) 
 
• More specific and sensitive 
 
1. Not always objective  
 
- Tend to be automated (hence not 
affected by knowledge of the 
exposed/unexposed, or case-control, 
status of subjects 
 
 
- But subjectivity may be introduced if 
subjects have to collaborate in the  
collection of specimens 
  
Limitations of exposure biomarkers: 
Limitations of exposure biomarkers: 
2. The wrong biomarker may be chosen for the 
exposure of interest: 
 
- it may not be specific to a single external exposure   
 
- the correct component(s) of a complex external exposure 
may not have been chosen (e.g. vit. A) 
 
-  biomarkers in surrogate tissues may not reflect events at 
the target site 
 
-it may measure early outcome rather than exposure 
 
Limitations of exposure biomarkers: 
2. The biomarker assay may have poor 
validity:  
 
- it is important to assess how well the test (biomarker 
assay) measures the true value of the exposure (the 
biomarker). 
 
» Validity (sensitivity and specificity) 
» Reliability (Kappa statistics, inter-
coefficient of variation) 
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3. Biomarker may not reflect measurement “at the 
right time”  
 
- Should reflect exposure at a time relevant aetiologically to the 
disease (often unknown) 
 
- Internal exposure may vary within an individual due to 
physiological processes, etc.  - short-term physiological variability 
 
Collection of specimens at multiple time points 
may be required to capture long-term exposure 
patterns 
Limitations of exposure biomarkers: 
Variation in oestradiol levels during the menstrual cycle 
The biomarker may not measure exposure 
at the relevant time: 
 
Biomarker   Average life span 
 
Haemoglobin-adducts    3 months 
Albumin-adducts    20-25 days 
Cellular DNA      hours-years 
 
3. Biomarker may not reflect measurement “at the 
right time”  
 
- Should reflect exposure at a time relevant aetiologically to the 
disease (often unknown) 
 
- Internal exposure may vary within an individual due to 
physiological processes, etc.  - short-term physiological variability 
 
Collection of specimens at multiple time points 
may be required to capture long-term exposure 
patterns 
Limitations of exposure biomarkers: 
 4. Biomarker may not reflect measurement “at the 
right site”  
 
- Requires knowledge of the kinetics of 
absorption, distribution, storage, metabolism 
and elimination from the body 
 
- Crucial to establish the correct site and 
time for sampling  
Limitations of exposure biomarkers: 
 5. Feasibility and costs  
 
- Nature of specimen collection (e.g. acceptability, 
safety, adversary effects) 
 
- Complexity of storage and processing logistics 
 
- Costs 
Limitations of exposure biomarkers: 
Biomarkers of exposure: quality control concerns 
 Minimise the effect of storage time by matching controls to 
cases on time of collection and duration of follow-up   
 
 Account for  other relevant variables such as number of 
freeze-thaw cycles 
 
 All samples should be send to the same lab (high-quality 
one) 
 
 Blind lab technicians to case-control status of the samples, 
exposure data and study hypothesis (avoid information bias) 
 
 
Biomarkers of exposure: quality control concerns 
 Use a common standardised protocol to perform the laboratory 
measurements (to minimises inter-assay variability).  
 
 Samples should be analysed in case-control pairs to minimize 
inter-batch variability.  
 
 Duplicate samples (with laboratory staff not being aware they 
are duplicates) should be randomly inserted within each batch 
to allow estimation of intra- and inter-batch variability.  
 
 A random selection of samples should be measured using a 
“gold standard” method (or sent to a reference laboratory, if 
there is one) to check the validity of the laboratory assays. 
 
 
Limitations of exposure biomarkers 
In summary: 
 
  exposure biomarkers have limitations 
 
  external exposure vs. exposure biomarkers? 
 
  
                 they measure different things! 
 
Biomarkers to measure susceptibility 
Individuals may have different susceptibility to the effect 
of external exposures 
 
E.g. individuals may differ in the way they: 
 
 absorb and metabolise the external exposure 
 
 repair DNA 
 
 respond to mutational events 
 
    External exposure 
Internal exposure 
Metabolised 
   Active metabolite (inactivated 
metabolite) 
DNA adduct in target cells 
DNA damage 
Early biological 
outcomes 
(DNA repair) 
* 
* 
* 
 * 
 * * 
* = differences in susceptibility 
When an internal exposure is metabolised, it may be: 
 
 activated: the metabolite can interact with target cells 
 
 inactivated: the metabolite can be excreted 
   
The metabolic activity of many activating and inactivating 
enzymes is determined genetically  
 
So, differences in activity can be measured using either 
phenotypic or genotypic biomarkers 
 
Biomarkers to measure susceptibility 
Biomarkers to measure susceptibility 
Example: 
 
N-acetyltransferase-2 (NAT2) is an enzyme that inactivates several 
carcinogens, including compounds present in cigarette smoke.  
 
NAT2 activity can be determined using: 
 
 Phenotypic tests - e.g., drug clearance tests (by 
administering a substance that is metabolised by NAT2 
to see how fast the metabolised substance is excreted 
from the body)  
 
 Genotypic tests – to assess the structure of the NAT2 
genes that code for the enzyme   
 
Fast vs. slow acetylators 
 
  Population-based case control study of history of 
smoking and acetylator type as risk factors for renal cell 
(kidney) cancer (RCC).  
 
 Smoking history was obtained at interview 
 
 Acetylator type was determined by characterising the 
NAT2 alleles 
(Semenza et al., 2001) 
Biomarkers to measure susceptibility 
Smoking status  Odds ratio for RRC   (n=374)     
 
Non Smokers   1.0  
Smokers            2.2 (1.3 - 3.7)   
 
Is the effect modified by acetylators status? 
 
Biomarkers to measure susceptibility 
   OR for effect of smoking on RCC  
 
Smoking     Slow acetylators     Fast acetylators 
 Status                       (n=195)   (n=179)  
 
Non Smokers   1.0    1.0  
Smokers       3.2 (1.7 - 6.1)  1.4 (0.7 - 2.9)   
     
       P for interaction = 0.04 
 
Is there evidence evidence of effect modification?   
   
Biomarkers to measure susceptibility 
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Biomarkers to measure early outcomes 
 
 Early outcomes are usually events on the causal 
pathway which lie between the biologically effective 
dose (BED) and clinical disease.   
 
 
 Can be subdivided into early and later biological effects, 
depending on how close they are to the clinical 
outcome.        
Biological effects preceding cancer of the colon: 
  
  Molecular changes: early changes include mutations which 
inactivate the tumour suppressor gene APC and cause 
dysregulation of the K-ras oncogene.  Later changes include 
mutations which inactivate the SMAD and p53 genes. 
 
  Cellular changes: early changes include proliferation of the 
cells lining the colon to form a polyp. Later changes include 
progressive dysplasia, and progress to cancerous cells.  
 
Biomarkers to measure early outcomes 
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Biomarkers to measure early outcomes 
 Early and late biological effects can be identified by carrying 
out natural history studies.   
 
 
 
 
 Once these early outcome biomarkers have been identified, 
they can be considered as outcomes in epidemiological 
studies. 
 
 
Biomarkers to measure early outcomes 
Early outcome biomarkers can be used to obtain earlier 
endpoints in studies.  This may be useful for: 
 
 Screening for pre-clinical disease 
 
 Analytical epidemiological studies 
 
 Monitoring variations in population health risk 
 
 
Biomarkers to measure early outcomes 
What is the advantage of using early outcomes in analytical 
studies? 
 
 
   Individuals can be followed up for a shorter period of time  
 
 
    The sample size of the study can be smaller  
Biomarkers to measure early outcomes 
Use of an early outcome biomarker may be limited if: 
 
 it is not a necessary cause of the clinical disease 
 
 it is not a sufficient cause of the clinical disease 
 
 it is an early outcome for more than one clinical disease 
 
 it is intermittently produced or unequally distributed throughout 
the tissue tested 
 
 its assay has imperfect validity or reliability 
 
 
Biomarkers to measure early outcomes 
An early outcome biomarker may not be a necessary cause of the disease 
- there may be more than one causal pathway for the clinical outcome.  
 
 
 
 
 
 
 
 
 
 
In this case, a positive K-ras biomarker will underestimate subsequent 
colon cancer. 
 
 
 
Biologically effective dose 
K-ras mutation Other mutations 
     Colon cancer 
Pathway 2 Pathway 1 
Biomarkers to measure early outcomes 
An early outcome biomarker may not be a sufficient cause of the 
disease that follows it.  
 
 
 
 
 
 
 
 
 
 
 
 
The K-ras mutation may not inevitably lead to colon cancer – subsequent mutations 
may also be needed.  
 
Thus, a positive K-ras biomarker may overestimate subsequent colon cancer. 
 
 
 
 
 
   Biologically effective dose 
K-ras mutation 
Colon cancer 
SMAD mutation 
P53 mutation 
Biomarkers to measure early outcomes 
The biomarker may not be specific to the disease of interest.   
 
 
 
 
 
 
 
 
 
A positive K-ras biomarker may overestimate subsequent colon cancer  
 
 
 
 
 
   Biologically effective dose 
K-ras mutation 
Colon cancer Pancreatic cancer 
Biomarkers to measure early outcomes 
Do understanding of disease mechanisms matter? 
Biomarkers can also be used to clarify the intermediate stages 
in disease pathogenesis  
 
• But: 
 
  - understanding disease mechanisms is  not essential for 
disease prevention 
Biomarkers to measure early outcomes 
However, knowledge of biological mechanisms may: 
 
- strengthen the evidence for a causal relationship 
between an exposure and a disease    
- identify biomarkers for use in epidemiological 
research  
- identify targets for preventative or therapeutic 
interventions     
- identify aetiologically distinct disease sub-types  
Do understand of disease mechanisms matter? 
Introduction to the use of biomarkers in research: 
summary 
• What are biomarkers? 
 
• Use of biomarkers to measure exposure  
 
• Use of biomarkers to measure susceptibility  
 
• Use of biomarkers to measure early outcomes  
 
• Use of biomarkers to clarify disease mechanisms  
 
• Limitations of biomarkers 
 
